NCT04230174 - Effect of Ocrelizumab on Neuroinflammation in Multiple Sclerosis as Measured by 11C-PBR28 MR-PET Imaging of Microglia Activation | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 29, 2020

Primary Completion Date

January 31, 2022

Study Completion Date

July 31, 2022

Conditions

Multiple Sclerosis

Interventions

DRUG

11C-PBR28

This study will evaluate, serially, functional and structural tissue changes in the cortex and WM of subjects with RRMS and progressive disease under Ocrelizumab using 11C-PBR28 MR-PET imaging at baseline and at approximately 12-month follow up.